- Home
- CRMD vs CHY Comparison
CRMD vs CHY Comparison
Compare CRMD & CHY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRMD
- CHY
- Stock Information
- Founded
- CRMD 2006
- CHY 2003
- Country
- CRMD United States
- CHY United States
- Employees
- CRMD N/A
- CHY N/A
- Industry
- CRMD Biotechnology: Pharmaceutical Preparations
- CHY Investment Managers
- Sector
- CRMD Health Care
- CHY Finance
- Exchange
- CRMD Nasdaq
- CHY Nasdaq
- Market Cap
- CRMD 876.7M
- CHY 905.6M
- IPO Year
- CRMD 2010
- CHY N/A
- Fundamental
- Price
- CRMD $9.79
- CHY $10.86
- Analyst Decision
- CRMD Strong Buy
- CHY
- Analyst Count
- CRMD 7
- CHY 0
- Target Price
- CRMD $17.43
- CHY N/A
- AVG Volume (30 Days)
- CRMD 3.1M
- CHY 128.3K
- Earning Date
- CRMD 11-12-2025
- CHY 01-01-0001
- Dividend Yield
- CRMD N/A
- CHY 10.11%
- EPS Growth
- CRMD N/A
- CHY N/A
- EPS
- CRMD 2.25
- CHY N/A
- Revenue
- CRMD $214,303,672.00
- CHY N/A
- Revenue This Year
- CRMD $565.64
- CHY N/A
- Revenue Next Year
- CRMD $46.09
- CHY N/A
- P/E Ratio
- CRMD $4.30
- CHY N/A
- Revenue Growth
- CRMD 1647.67
- CHY N/A
- 52 Week Low
- CRMD $5.60
- CHY $9.97
- 52 Week High
- CRMD $17.43
- CHY $12.16
- Technical
- Relative Strength Index (RSI)
- CRMD 38.57
- CHY 35.87
- Support Level
- CRMD $9.45
- CHY $10.68
- Resistance Level
- CRMD $10.40
- CHY $11.24
- Average True Range (ATR)
- CRMD 0.68
- CHY 0.22
- MACD
- CRMD -0.14
- CHY -0.09
- Stochastic Oscillator
- CRMD 13.66
- CHY 25.89
About CRMD CorMedix Inc.
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States (U.S.) and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.
About CHY Calamos Convertible and High Income Fund
Calamos Convertible & High Income Fund is a diversified, closed-end management investment company. Its objective is to provide total return through a combination of capital appreciation and current income. The firm invests in a diversified portfolio of convertible securities and high-yield securities.